Page last updated: 2024-09-04

ezetimibe and Myocardial Infarction

ezetimibe has been researched along with Myocardial Infarction in 68 studies

Research

Studies (68)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	12 (17.65)	29.6817
2010's	26 (38.24)	24.3611
2020's	30 (44.12)	2.80

Authors

Authors	Studies
Cho, J; Choi, JH; Choi, KH; Choi, SH; Guallar, E; Gwon, HC; Hahn, JY; Kang, D; Kang, M; Kim, J; Lee, JM; Park, H; Park, TK; Song, YB; Yang, JH	1
Blazing, MA; Braunwald, E; Cannon, CP; Giugliano, RP; Oyama, K; Park, JG; Sabatine, MS; Tershakovec, AM	1
Barthélémy, O; Brugier, D; Collet, JP; Guedeney, P; Kerneis, M; Lattuca, B; Mertens, E; Montalescot, G; Posson, J; Procopi, N; Sabouret, P; Salloum, T; Silvain, J; Sulman, D; Zeitouni, M	1
Huffman, MD; Rodgers, A; Wang, N; Woodward, M	1
Aertgeerts, B; Bekkering, GET; Delvaux, N; Guyatt, G; Hao, Q; Khan, SU; Li, S; Lone, AN; Riaz, IB; Rodondi, N; Vandvik, PO; Yedlapati, SH	1
Aertgeerts, B; Agoritsas, T; Al Ansary, L; Assendelft, WJJ; Bekkering, GE; Dawson, A; Delvaux, N; Guyatt, G; Hao, Q; Heen, AF; Jackson, R; Khan, SU; Li, S; Lytvyn, L; Okwen, PM; Ovidiu, MC; Ramaekers, D; Reny, JL; Riaz, IB; Rodondi, N; Siemieniuk, RAC; Spencer, F; Van Driel, M; Vanbrabant, W; Vandvik, PO; Zhao, Q; Zhu, Y	1
Boch, T; Michaeli, DT; Michaeli, JC; Michaeli, T	1
Boytsov, SA; Erlikh, AD; Kukava, NG; Pevsner, DV; Rytova, YK; Shakhnovich, RM; Tereschenko, SN	1
Ennezat, PV; François, P; Guerbaai, RA; Le Jemtel, TH; Maréchaux, S	1
Damasceno, NRT; Fonseca, FAH; Izar, MC; Lotfollahi, Z; Machado, LO; Mathias, AF; Mello, APQ; Neto, AMF; Oliveira, CLP	1
Chickballapur Ramachandrachar, B; Chilukuri, SH; Farghaly, M; Natarajan, A; Nunna, S; Pinto, L	1
Cai, X; Han, X; Ji, L; Lin, C; Lv, F; Yang, W; Zhu, X	1
Bress, AP; Brown, TM; Derington, CG; Exter, J; Herrick, JS; Jackson, EA; Muntner, P; Orroth, K; Poudel, B; Reading, S; Rosenson, RS; Safford, MM; Virani, SS; Woodward, M; Zheutlin, AR	1
Jiang, GT; Liu, H; Liu, J; Lou, B; Luo, Y; She, J; Wang, C; Wu, H; Wu, Y; Yuan, Z; Zhou, B	1
Antoniou, S; Brachmann, J; Cornel, JH; Ferguson, S; González-Juanatey, JR; Perrone-Filardi, P; Qureshi, N; Rowlands, C; Schiele, F; Sidelnikov, E; Villa, G	1
Sawant, S; Wang, N	1
Ahn, CM; Choi, D; Choi, DW; Hong, MK; Hong, SJ; Jang, Y; Joo, JH; Kim, BK; Kim, C; Kim, JS; Ko, YG; Lee, SJ; Nam, CM; Park, S	1
Glorioso, TJ; Gupta, P; Ho, PM; Kovach, CP; Mesenbring, EC; Schwartz, GG; Waldo, SW	1
Arashi, H; Hagiwara, N; Haruta, S; Ishii, Y; Kawada-Watanabe, E; Koyanagi, R; Mori, F; Murasaki, S; Ogawa, H; Sekiguchi, H; Suzuki, K; Yamaguchi, J; Yamauchi, T	1
Kang, LN; Lan, RF; Wang, L; Xu, B; Xu, W; Zhang, XL; Zhang, XW	1
Ambrosio, G; Armstrong, PW; De Ferrari, GM; Green, JB; Holman, RR; Leonardi, S; Peterson, ED; Stevens, SR; Wamil, M	1
Allahyari, A; Hagström, E; Jernberg, T; Leosdottir, M; Lundman, P; Ueda, P	1
Khan, SA; Naz, A; Qamar Masood, M; Shah, R	1
Carter, JL; Casas, JP; Hingorani, AD; Overington, JP; Pearce, LS; Schmidt, AF; Wilkins, JT	1
Braunwald, E; Cannon, CP; Gencer, B; Giugliano, RP; Im, K; Keech, A; Marston, NA; Sabatine, MS; Sever, P	1
Alkhouli, M; Blaha, MJ; Blumenthal, RS; Kalra, A; Khan, MS; Khan, MU; Khan, MZ; Khan, SU; Michos, ED; Rashid, M; Virani, SS	1
Abdallah, R; Ali, AH; Ayoub, MA; Dakroub, A; Eid, AH; El-Yazbi, AF; Iratni, R; Orekhov, A; Shaer, F; Yassine, HM; Younis, N; Zibara, K	1
Chauny, JV; Desamericq, G; Gusto, G; Kahangire, D; Khachatryan, A; Quignot, N; Ricci, L; Schiele, F; Villa, G	1
Everson, K; Lakdawalla, DN; Lautsch, D; Liu, L; MacEwan, JP; Sun, F; Zhao, LM	1
Amarenco, P; Bruckert, E; Charles, H; Giroud, M; Kim, JS; Labreuche, J; Lavallée, PC; Lee, BC; Mahagne, MH; Meseguer, E; Nighoghossian, N; Steg, PG; Vicaut, É	1
Bastos, RT; Cruz, ECS; Derogis, PBMC; Dos Santos Ferreira, CE; Faccio, AT; Fonseca, FAH; Fontoura, SC; Izar, MC; Klassen, A; Lopes, AS; Neto, AMF; Picossi, CRC; Sussulini, A; Tavares, MFM	1
Ako, J; Arai, H; Harada-Shiba, M; Hirayama, A; Nakamura, M; Nohara, A; Uno, K	1
Alahmari, A; Almalki, ZS; Alotaibi, N; Guo, JJ; Thaibah, H	1
Clemens, KK; Hegele, RA; McArthur, E; Shariff, SZ	1
Chen, Y; Liu, L	1
Liu, F; Shu, M; Tang, M; Wu, X; Xia, P; Zhan, S	1
Hovingh, GK; Ray, KK; Reeskamp, LF	1
Hattori, E; Hirao, K; Kasano, K; Matsumoto, S; Nakamura, S; Teng, Y; Tokunaga, T; Yamamoto, T; Yonetsu, T; Yoshiwara, H	1
Cannon, CP; D'Agostino, RB; Khan, I; Klimchak, AC; Massaro, JM; Reynolds, MR; Sanchez, RJ; Sasiela, WJ	1
Špinar, J; Špinarová, L; Vítovec, J	1
Frikke-Schmidt, R; Lauridsen, BK; Nordestgaard, BG; Stender, S; Tybjærg-Hansen, A	1
Stiefelhagen, P	1
Blazing, MA; Bohula, EA; Braunwald, E; Cannon, CP; Giugliano, RP; Murphy, SA; Tershakovec, AM; White, JA; Zhou, J	1
Blazing, MA; Bohula, EA; Braunwald, E; Cannon, CP; Dellborg, M; Giugliano, RP; Im, K; Isaza, D; Kher, U; Lokhnygina, Y; Lopez-Sendon, J; Murphy, SA; Reist, C; Tershakovec, AM; White, JA	1
Murphy, J; Wright, RS	1
Albers, JJ; Fleg, JL; Marcovina, SM; O'Brien, KD; Slee, A	1
Briguori, C; Calabrò, P; Condorelli, G; De Caterina, R; Madonna, R; Quintavalle, C; Salomone, M; Zimarino, M	1
Anderson, ML; Blasi, PR; Dunn, J; Henrikson, NB; Lozano, P; Morrison, CC; Nguyen, M; Whitlock, EP	1
Ahn, YK; Bae, JH; Chae, JK; Chae, SC; Cho, MC; Hong, TJ; Jeong, MH; Ji, MS; Kim, CJ; Kim, SH; Kim, YJ; Park, SJ; Rha, SW; Seong, IW; Seung, KB	1
Bays, HE; Chaudhari, U; Jones, PH; Lorenzato, C; Miller, K; Pordy, R; Robinson, JG	1
Antonsen, L; Hansen, HS; Hougaard, M; Jensen, LO; Junker, A; Thayssen, P; Veien, K	1
Blazing, MA; Bohula, EA; Brady, AJ; Braunwald, E; Cannon, CP; Giugliano, RP; He, P; Kesaniemi, YA; Mitchel, Y; Morrow, DA; Murphy, SA; Park, JG; Pedersen, TR; White, JA	1
Elsais, A; Kerty, E; Lund, C	1
Cervera, R; Escárcega, RO; Garcia-Carrasco, M; Jara, LJ	1
Schunn, H	1
Chong, E; Poh, KK; Shen, L	1
Boman, K; Devereux, RB; Egstrup, K; Gohlke-Baerwolf, C; Greve, AM; Kesäniemi, YA; Køber, L; Nienaber, C; Ray, S; Rossebø, AB; Wachtell, K; Willenheimer, R	1
Bestehorn, K; Gitt, AK; Jannowitz, C; Karmann, B; Pittrow, D; Schaefer, JR; Sonntag, F; Weizel, A	1
Ambrosi, P; Andréjak, M; Gayet, JL	1
Bruckert, E; Giral, P; Tellier, P	1
SoRelle, R	1
von Hodenberg, E	1
Blaimont, M; Chenot, F; de Meester, A; Descamps, OS; Marcovitch, O; Montant, PF	1
Allen, C; Brudi, P; Henry, P; Johnson-Levonas, AO; Lim, ST; Lis, K; Massaad, R; Pomykaj, T; Reckless, JP; Vandormael, K	1
Birnbaum, Y; Lin, Y; Merla, R; Perez-Polo, JR; Uretsky, BF; Ye, Y	1

Reviews

18 review(s) available for ezetimibe and Myocardial Infarction

Article	Year
Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis. Circulation. Cardiovascular quality and outcomes, 2022, Volume: 15, Issue:6 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Risk Factors	2022
PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. BMJ (Clinical research ed.), 2022, 05-04, Volume: 377 Topics: Adult; Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Network Meta-Analysis; PCSK9 Inhibitors; Proprotein Convertase 9; Risk Factors; Stroke	2022
PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. BMJ (Clinical research ed.), 2022, 05-04, Volume: 377 Topics: Adult; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; PCSK9 Inhibitors; Proprotein Convertase 9; Stroke	2022
Extent of Low-density Lipoprotein Cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: A Systematic Review and Meta-analysis. Journal of cardiovascular pharmacology, 2023, 01-01, Volume: 81, Issue:1 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Randomized Controlled Trials as Topic	2023
Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials. Medicine, 2022, Sep-16, Volume: 101, Issue:37 Topics: Antibodies, Monoclonal; C-Reactive Protein; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Proprotein Convertase 9; Randomized Controlled Trials as Topic; Subtilisins	2022
Under-representation of ethnic and regional minorities in lipid-lowering randomized clinical trials: a systematic review and meta-analysis. European journal of preventive cardiology, 2023, 08-21, Volume: 30, Issue:11 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Stroke	2023
Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 2019, 08-20, Volume: 8, Issue:16 Topics: Anticholesteremic Agents; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Myocardial Revascularization; Stroke; Treatment Outcome	2019
Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia. The American journal of cardiology, 2020, 11-01, Volume: 134 Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Anticholesteremic Agents; Apolipoproteins B; Aspartate Aminotransferases; Bilirubin; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Injection Site Reaction; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; RNA, Small Interfering; Stroke	2020
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. The Cochrane database of systematic reviews, 2020, 10-20, Volume: 10 Topics: Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Cholinergic Antagonists; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; PCSK9 Inhibitors; Primary Prevention; Proprotein Convertase 9; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Time Factors	2020
Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet (London, England), 2020, 11-21, Volume: 396, Issue:10263 Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Stroke; Treatment Outcome	2020
Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis. European journal of preventive cardiology, 2022, 02-09, Volume: 28, Issue:18 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction	2022
Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies. Current medicinal chemistry, 2021, Volume: 28, Issue:36 Topics: Antibodies, Monoclonal; Atherosclerosis; Cholesterol, LDL; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Proprotein Convertase 9	2021
Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. The Cochrane database of systematic reviews, 2018, 11-19, Volume: 11 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Simvastatin; Stroke; Triglycerides	2018
Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA, 2016, Aug-09, Volume: 316, Issue:6 Topics: Adolescent; Advisory Committees; Biomarkers; Carotid Intima-Media Thickness; Child; Cholesterol; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Mass Screening; Myocardial Infarction; Observational Studies as Topic; Preventive Health Services; Simvastatin; Stroke; United States	2016
[Lipid therapy in daily routine]. Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:40 Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Ezetimibe; Female; General Practice; Germany; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Practice Patterns, Physicians'; Prospective Studies; Simvastatin	2012
[The best of clinical pharmacology in 2002]. Archives des maladies du coeur et des vaisseaux, 2003, Volume: 96 Spec No 1 Topics: Anticholesteremic Agents; Antihypertensive Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; Hormone Replacement Therapy; Humans; Hydrazones; Hypercholesterolemia; Losartan; Myocardial Infarction; Natriuretic Agents; Natriuretic Peptide, Brain; Neovascularization, Physiologic; Nicorandil; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Vasodilator Agents	2003
Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation, 2003, Jul-01, Volume: 107, Issue:25 Topics: Adolescent; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Male; Middle Aged; Myocardial Infarction; Treatment Outcome	2003
[Optimization of cholesterol reduction principles and clinical results of dual inhibition]. Der Internist, 2005, Volume: 46 Suppl 1 Topics: Azetidines; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Drug Combinations; Ezetimibe; Germany; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Myocardial Infarction; Practice Patterns, Physicians'; Treatment Outcome	2005

Trials

16 trial(s) available for ezetimibe and Myocardial Infarction

Article	Year
Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. Journal of the American College of Cardiology, 2021, 10-12, Volume: 78, Issue:15 Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Simvastatin	2021
Changes in lipoproteins associated with lipid-lowering and antiplatelet strategies in patients with acute myocardial infarction. PloS one, 2022, Volume: 17, Issue:8 Topics: Anticholesteremic Agents; Clopidogrel; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Myocardial Infarction; Prospective Studies; Rosuvastatin Calcium; Scattering, Small Angle; Simvastatin; Ticagrelor; X-Ray Diffraction	2022
Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ-PROPER. Journal of the American Heart Association, 2019, 08-20, Volume: 8, Issue:16 Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Anticholesteremic Agents; Arachidonic Acid; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Fatty Acids, Unsaturated; Female; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Prognosis; Quinolines; Risk Assessment; Stroke	2019
Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS. American heart journal, 2020, Volume: 220 Topics: Aged; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Reference Values; Sitagliptin Phosphate; Stroke	2020
Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction. Scientific reports, 2021, 08-05, Volume: 11, Issue:1 Topics: Anticholesteremic Agents; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Lipids; Male; Middle Aged; Myocardial Infarction; Rosuvastatin Calcium; Simvastatin; ST Elevation Myocardial Infarction	2021
Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial. Heart, lung & circulation, 2018, Volume: 27, Issue:6 Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Brain Ischemia; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Quality-Adjusted Life Years; Saudi Arabia; Simvastatin; Treatment Outcome	2018
[IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (studie IMPROVE-IT)]. Vnitrni lekarstvi, 2014, Volume: 60, Issue:12 Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Simvastatin	2014
[Even lower values are even better!]. MMW Fortschritte der Medizin, 2015, Aug-20, Volume: 157, Issue:14 Topics: Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Myocardial Infarction; Risk Factors; Simvastatin; Stroke	2015
Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation, 2015, Sep-29, Volume: 132, Issue:13 Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cerebral Revascularization; Cholesterol, LDL; Comorbidity; Creatinine; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Electrocardiography; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Simvastatin; Treatment Outcome	2015
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. Journal of the American College of Cardiology, 2016, Feb-02, Volume: 67, Issue:4 Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Simvastatin; Survival Rate; Time Factors; Treatment Outcome; United States	2016
Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial. Atherosclerosis, 2016, Volume: 251 Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cardiovascular System; Cholesterol, HDL; Cohort Studies; Coronary Artery Disease; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Niacin; Proportional Hazards Models; Simvastatin; Treatment Outcome; Triglycerides	2016
Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial. Cardiovascular drugs and therapy, 2016, Volume: 30, Issue:5 Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Cardiotonic Agents; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Percutaneous Coronary Intervention; Rosuvastatin Calcium; Treatment Outcome	2016
Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular revascularization medicine : including molecular interventions, 2017, Volume: 18, Issue:2 Topics: Aged; Atorvastatin; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Myocardial Infarction; Treatment Outcome; Ultrasonography, Interventional	2017
Clinical implications of electrocardiographic left ventricular strain and hypertrophy in asymptomatic patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study. Circulation, 2012, Jan-17, Volume: 125, Issue:2 Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Azetidines; Cardiovascular Diseases; Drug Therapy, Combination; Electrocardiography; Ezetimibe; Female; Follow-Up Studies; Heart Failure; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardial Infarction; Prognosis; Simvastatin; Ventricular Dysfunction, Left	2012
Co-administration of ezetimibe and simvastatin in acute myocardial infarction. European journal of clinical investigation, 2007, Volume: 37, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Simvastatin; Triglycerides	2007
Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. International journal of clinical practice, 2008, Volume: 62, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Myocardial Infarction; Simvastatin; Treatment Outcome	2008

Other Studies

34 other study(ies) available for ezetimibe and Myocardial Infarction

Article	Year
Moderate-Intensity Statins Plus Ezetimibe vs. High-Intensity Statins After Coronary Revascularization: A Cohort Study. Cardiovascular drugs and therapy, 2023, Volume: 37, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Cohort Studies; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Rosuvastatin Calcium; Stroke; Treatment Outcome	2023
ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2. European heart journal. Cardiovascular pharmacotherapy, 2022, Sep-03, Volume: 8, Issue:6 Topics: Anticholesteremic Agents; Cardiology; Cholesterol; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Practice Guidelines as Topic; Proprotein Convertase 9; ST Elevation Myocardial Infarction	2022
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy. Clinical drug investigation, 2022, Volume: 42, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Cost-Benefit Analysis; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Proprotein Convertase 9; Quality-Adjusted Life Years; State Medicine	2022
The prevalence of hyperlipidemia and features of lipid-lowering therapy in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI. Kardiologiia, 2022, Jul-31, Volume: 62, Issue:7 Topics: Anticholesteremic Agents; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Myocardial Infarction; PCSK9 Inhibitors; Prevalence; Proprotein Convertase 9; Retrospective Studies; Russia	2022
Lipid lowering therapy patterns and the risk of cardiovascular events in the 1-year after acute myocardial infarction in United Arab Emirates. PloS one, 2022, Volume: 17, Issue:9 Topics: Aftercare; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Patient Discharge; Retrospective Studies; United Arab Emirates	2022
Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019. Circulation. Cardiovascular quality and outcomes, 2022, Volume: 15, Issue:12 Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; United States; Veterans	2022
In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction. Lipids in health and disease, 2022, Oct-24, Volume: 21, Issue:1 Topics: Antibodies, Monoclonal; Anticholesteremic Agents; Cholesterol, LDL; Ezetimibe; Female; Hospitals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; PCSK9 Inhibitors; Proprotein Convertase 9; Subtilisins	2022
European Physician Survey Characterizing the Clinical Pathway and Treatment Patterns of Patients Post-Myocardial Infarction. Advances in therapy, 2023, Volume: 40, Issue:1 Topics: Anticholesteremic Agents; Cholesterol, LDL; Critical Pathways; Cross-Sectional Studies; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Physicians	2023
Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2023, 08-01, Volume: 82, Issue:5 Topics: Anticholesteremic Agents; Drug Therapy, Combination; Drug-Eluting Stents; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Myocardial Infarction; Percutaneous Coronary Intervention; Rosuvastatin Calcium; Treatment Outcome	2023
Projected Outcomes of Optimized Statin and Ezetimibe Therapy in US Military Veterans with Coronary Artery Disease. JAMA network open, 2023, 08-01, Volume: 6, Issue:8 Topics: Aged; Cholesterol, LDL; Cohort Studies; Coronary Artery Disease; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; United States; Veterans	2023
Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study. European heart journal, 2020, 10-21, Volume: 41, Issue:40 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Cardiology; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; PCSK9 Inhibitors; Percutaneous Coronary Intervention; Young Adult	2020
Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: Five years of clinical follow-up from 164,565 post-myocardial infarction patients. International journal of cardiology, 2021, 06-01, Volume: 332 Topics: Aged; Ezetimibe; Female; Follow-Up Studies; France; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction	2021
Two steps forward, one step back: 50 years of societal value from LDL-C-lowering therapies. The American journal of managed care, 2021, Volume: 27, Issue:4 Topics: Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Nutrition Surveys	2021
Impact of Lower Versus Higher LDL Cholesterol Targets on Cardiovascular Events After Ischemic Stroke in Patients With Diabetes. Diabetes, 2021, Volume: 70, Issue:8 Topics: Aged; Cholesterol, LDL; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Stroke; Male; Middle Aged; Myocardial Infarction; Treatment Outcome	2021
Exploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study. BMJ open, 2017, 07-02, Volume: 7, Issue:6 Topics: Acute Coronary Syndrome; Angina, Unstable; Anticholesteremic Agents; Ezetimibe; Fibric Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Incidence; Ischemic Attack, Transient; Japan; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Revascularization; Observational Studies as Topic; PCSK9 Inhibitors; Prevalence; Proprotein Convertase 9; Prospective Studies; Registries; Research Design; Risk Factors; Stroke	2017
Ezetimibe prescriptions in older Canadian adults after an acute myocardial infarction: a population-based cohort study. Lipids in health and disease, 2018, Jan-08, Volume: 17, Issue:1 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Canada; Cohort Studies; Databases, Factual; Drug Prescriptions; Ezetimibe; Female; Hospitalization; Humans; Male; Myocardial Infarction; Sex Factors	2018
Is the decrease of triglyceride level after acute myocardial infarction within a month by the effect of combination therapy of Ezetimibe and Simvastatin. International journal of cardiology, 2018, 04-01, Volume: 256 Topics: Anticholesteremic Agents; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Simvastatin; Treatment Outcome; Triglycerides	2018
Hypercholesterolemia Among Premature Infarcts: Time to Start the Clock of Familial Hypercholesterolemia Assessment. Journal of the American College of Cardiology, 2019, 05-21, Volume: 73, Issue:19 Topics: Ezetimibe; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Infarction; Myocardial Infarction; Proprotein Convertase 9; Young Adult	2019
Impact of intensively lowered low-density lipoprotein cholesterol on deferred lesion prognosis. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2020, 03-01, Volume: 95, Issue:4 Topics: Aged; Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Down-Regulation; Dyslipidemias; Ezetimibe; Female; Fractional Flow Reserve, Myocardial; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Time-to-Treatment; Treatment Outcome	2020
Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. American heart journal, 2019, Volume: 216 Topics: Aged; Angina, Unstable; Antibodies, Monoclonal, Humanized; Atherosclerosis; Cause of Death; Cholesterol, LDL; Cohort Studies; Elective Surgical Procedures; Ezetimibe; Female; Hospitalization; Humans; Hypolipidemic Agents; Insurance, Health, Reimbursement; Male; Medication Adherence; Middle Aged; Monte Carlo Method; Myocardial Infarction; Percutaneous Coronary Intervention; Proportional Hazards Models; Risk; Stroke	2019
Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease. European heart journal, 2015, Jul-01, Volume: 36, Issue:25 Topics: Aged; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Gallstones; Genetic Variation; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemia; Lipid Metabolism; Male; Membrane Proteins; Membrane Transport Proteins; Mendelian Randomization Analysis; Middle Aged; Myocardial Infarction; Risk Factors; Stroke	2015
PROVE-IT to IMPROVE-IT: Why LDL-C Goals Still Matter in Post-ACS Patients. Journal of the American College of Cardiology, 2016, Feb-02, Volume: 67, Issue:4 Topics: Acute Coronary Syndrome; Ezetimibe; Female; Humans; Male; Myocardial Infarction; Simvastatin	2016
Clinical outcome of statin plus ezetimibe versus high-intensity statin therapy in patients with acute myocardial infarction propensity-score matching analysis. International journal of cardiology, 2016, Dec-15, Volume: 225 Topics: Aged; Anticholesteremic Agents; Coronary Angiography; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Propensity Score; Registries; Republic of Korea; Retrospective Studies; Treatment Outcome	2016
Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials. The American journal of cardiology, 2016, Dec-15, Volume: 118, Issue:12 Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Back Pain; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Comorbidity; Coronary Disease; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Influenza, Human; Middle Aged; Myocardial Infarction; Nasopharyngitis; Pruritus; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Stroke; Urinary Tract Infections	2016
Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. Journal of the American College of Cardiology, 2017, Feb-28, Volume: 69, Issue:8 Topics: Acute Coronary Syndrome; Aged; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Risk Assessment; Secondary Prevention; Simvastatin; Treatment Outcome	2017
[Stable coronary heart disease--lessons from the COURAGE Study. With intensive drug therapy on the success track]. MMW Fortschritte der Medizin, 2008, Jun-05, Volume: 150, Issue:23 Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Azetidines; Cardiovascular Agents; Combined Modality Therapy; Coronary Disease; Coronary Stenosis; Death, Sudden, Cardiac; Ezetimibe; Humans; Kaplan-Meier Estimate; Life Style; Multicenter Studies as Topic; Myocardial Infarction; Outcome and Process Assessment, Health Care; Randomized Controlled Trials as Topic; Simvastatin	2008
Ptosis, diplopia and statins: an association? European journal of neurology, 2008, Volume: 15, Issue:10 Topics: Adult; Atorvastatin; Autoantibodies; Autoimmune Diseases of the Nervous System; Azetidines; Blepharoptosis; Diabetes Complications; Diagnostic Errors; Diplopia; Eyelid Diseases; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Myasthenia Gravis; Myocardial Infarction; Pain; Pravastatin; Pyrroles; Receptors, Cholinergic; Recurrence; Strabismus	2008
Accelerated atherosclerosis in systemic lupus erythematosus: perspectives towards decreasing cardiovascular morbidity and mortality. Lupus, 2009, Volume: 18, Issue:5 Topics: Aspirin; Azetidines; Clinical Trials as Topic; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk	2009
The Zetia challenge: an update. The Johns Hopkins medical letter health after 50, 2009, Volume: 21, Issue:2 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Ezetimibe; Humans; Myocardial Infarction	2009
[On the current debate on lowering LDL cholesterol with ezetimibe]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:44 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Financing, Personal; Fluorobenzenes; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Myocardial Infarction; National Health Programs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides	2010
Half-dose ezetimibe add-on to statin therapy is effective in improving resistant hyperlipidaemia in Asian patients with ischaemic heart disease. Singapore medical journal, 2011, Volume: 52, Issue:6 Topics: Aged; Asia; Azetidines; Cholesterol; Cohort Studies; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Simvastatin; Treatment Outcome	2011
[Ezetimib--the first selective cholesterol resorption inhibitors. Strengthening of statins]. MMW Fortschritte der Medizin, 2002, Nov-28, Volume: 144, Issue:48 Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hypolipidemic Agents; Myocardial Infarction; Risk Factors; Time Factors; Triglycerides	2002
Stenosis and the drug-eluting stent. Circulation, 2004, Mar-23, Volume: 109, Issue:11 Topics: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Azetidines; Cardiology; Coronary Restenosis; Diabetes Complications; Ezetimibe; Humans; Hypercholesterolemia; Myocardial Infarction; Myocardial Ischemia; Perindopril; Radionuclide Imaging; Randomized Controlled Trials as Topic; Stents	2004
Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat. Journal of cardiovascular pharmacology and therapeutics, 2008, Volume: 13, Issue:1 Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Up-Regulation	2008